Pharmaceutical Business Review
Anonymous User | Login

Summit, Biomarin Restructures Muscular Dystrophy Agreement

Published: 29-May-2009

Summit and BioMarin have restructured their agreement for the Duchenne muscular dystrophy (DMD) program, under which Summit received an equity investment of $7 million at the time.

Under the terms of the restructured deal, BioMarin has acquired full ownership of the DMD program, including the preclinical candidate, SMT C1100.

BioMarin has assumed all future preclinical and nonclinical development costs for SMT C1100, that were to be borne by Summit under the original licensing agreement.

Summit is now ready to receive success-based development and regulatory milestones of up to $50 million, plus sales milestones of up to $85 million and tiered royalty payments rising to a low-teen percentage.

Share

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Aptuit

Drug Discovery and Development ...

AR2i

Liquid Handling, Laboratory Material and Technology, Aparatus, Automation and Glassware ...

Aveva Drug Delivery Systems

Innovative Drug Delivery Solutions ...

bbi-biotech

Fully automated and sterile sampling systems ...

BINDER

Best Conditions for Your Success ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GRACO's New FDA Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New Hydra-Clean

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New 1590 & 3150 Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Customer Testimonial – Astra Zeneca

From the control room to the downstream processing area and with an eye on utilities servi ...

Hygienic Processing

From the control room to the downstream processing area and with an eye on utilities servi ...

Related Companies

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. (BioMarin) is principally engaged in the development and c ...

Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals (Enzon), a biopharmaceutical company, is engaged in the developme ...

Altus Pharmaceuticals Inc.

Altus Pharmaceuticals Inc. (Altus) is a biopharmaceutical company engaged in the develo ...

Shire Plc

Shire Plc (Shire) is specialty pharmaceutical company, chiefly focused on the research, ...

Suppliers Product News

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres Tts®

Par to begin shipping clonidine TDS in the near future.

Aveva's Partner Receives FDA Approval for Onsolis

FDA approves opioid pain reliever with required risk reduction plan.

Teva Announces FDA Approval and Commercial Launch of Fentanyl Transdermal System

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address